News Links
Celiac News for September 21, 2016
Bifidobacterium infantis NLS Super Strain Reduces the Expression of α-Defensin-5, a Marker of Innate Immunity, in the Mucosa of Active Celiac Disease Patients. The industrial food additive, microbial transglutaminase, mimics tissue transglutaminase and is immunogenic in celiac disease patients. Celiac disease and the risk of kidney diseases: A systematic review and meta-analysis. Celiac Disease is Misdiagnosed Based on Serology Only in a Substantial Proportion of Patients.
Read MoreDaily Care News for September 21, 2016
Novel glucose-sensing technology and hypoglycaemia in type 1 diabetes: a multicentre, non-masked, randomized controlled trial. Continuous glucose monitoring for patients with type 1 diabetes and impaired awareness of hypoglycaemia (IN CONTROL): a randomized, open-label, crossover trial. Glycemic control and maternal and fetal outcomes in pregnant women with type 1 diabetes according to the type of basal insulin. Efficacy of the READY-Girls Program on General Risk-Taking Behaviors, Condom Use, and Sexually Transmitted Infections Among Young Adolescent Females With Type 1 Diabetes. Qualitative assessment of user experiences of a novel smart phone application designed to support flexible intensive insulin therapy in type […]
Read MoreResearch News From September 21, 2016
Safety of a Hybrid Closed-Loop Insulin Delivery System in Patients With Type 1 Diabetes. PDF available with free JAMA account login. Early Detection of Infusion Set Failure During Insulin Pump Therapy in Type 1 Diabetes. Modelling Day-to-Day Variability of Glucose-Insulin Regulation over 12-Week Home Use of Closed-Loop Insulin Delivery. Free full text available in PDF format. Dipeptidyl peptidase-4 activity is associated with urine albumin excretion in type 1 diabetes. Type 1 diabetes in Sardinia: facts and hypotheses in the context of worldwide epidemiological data. Thinking outside the insulin box: McMaster researchers link improved muscle health to better outcomes for people […]
Read MorePress Releases for September 14, 2016
Glooko and Diasend Merge to Deliver the World’s Premier Diabetes Management Platform.
Read MorePopular Press for September 14, 2016
‘Longstanding scandal’: Huge insulin price hikes worse than EpiPen’s, experts say. UK commercial pilots with diabetes and treated with insulin can fly with no safety concerns. Hudson child ambassador for Nick Jonas’ diabetes organization. The diary of a girl with the little known eating disorder ‘diabulimia’. Diabulimia: Diabetes and eating disorder service launching in UK. JDRF backs Sernova’s implant for T1D. Novel SGLT Inhibitor Adds Benefit to Insulin in Type 1 Diabetes (free Medscape membership required). What type 1 diabetes taught this doctor-to-be about medicine, family and life. How pro cyclists make it in a cash-starved sport. Miss America 2017: Miss […]
Read MoreCeliac News for September 14, 2016
Computer-aided texture analysis combined with experts’ knowledge: Improving endoscopic celiac disease diagnosis. Free full text available in HTML and PDF formats. The clinical and phenotypical assessment of seronegative villous atrophy; a prospective UK center experience evaluating 200 adult cases over a 15-year period (2000-2015). Younger White Women Are Behind The Surge Of Gluten-Free Diets.
Read MoreDaily Care News for September 14, 2016
A Comprehensive Performance Evaluation of Five Blood Glucose Systems in the Hypo-, Eu-, and Hyperglycemic Range. Switching from twice-daily glargine or detemir to once-daily degludec improves glucose control in type 1 diabetes. An observational study. Clinical and economic benefits of integrated pump/CGM technology therapy in patients with type 1 diabetes in Colombia. Can Families Eat Better Without Spending More? Improving Diet Quality Does Not Increase Diet Cost in a Randomized Clinical Trial among Youth with Type 1 Diabetes and Their Parents. Characterization of Exercise and Alcohol Self-Management Behaviors of Type 1 Diabetes Patients on Insulin Pump Therapy. Diabetes distress in […]
Read MoreResearch News From September 14, 2016
Home Use of Day-and-Night Hybrid Closed-Loop Insulin Delivery in Suboptimally Controlled Adolescents With Type 1 Diabetes: A 3-Week, Free-Living, Randomized Crossover Trial. A minimized human insulin-receptor-binding motif revealed in a Conus geographus venom insulin. See also Snails’ speedy insulin: Bio-inspired insulin may act three times faster than current products and Snail venom holds key to better diabetes treatments. Increased skin autofluorescence of children and adolescents with type 1 diabetes despite a well-controlled HbA1c: results from a cohort study. Free full text available in HTML and PDF formats. Skin Autofluorescence is Associated with Early-stage Atherosclerosis in Patients with Type 1 Diabetes. […]
Read More